Glyburide to protect the spinal cord after injury
Part of Brain & nervous system, Injuries & trauma clinical trials.
This Phase 1 trial tests whether glyburide, a drug used for blood sugar, can help protect nerve tissue after an acute spinal cord injury. It’s mainly focused on safety and early signs that the treatment might be beneficial for people with certain levels of spinal cord damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your spinal cord injury is recent and in the neck (C2–C8) or upper/mid back (T1–T12).
- Your neurologic exam on admission must be ASIA grade A, B, or C (not D or E).
- Your injury is non-penetrating (not from an object entering the body).
- You are not in a life-threatening situation from the accident, and there is no sepsis (serious body infection).
- You can be assessed for your nerves within the first 8 hours (not unconscious or unable to cooperate).
- You do not have key medical reasons that make glyburide unsafe, like sulfonylurea allergy, severe kidney or liver problems, or certain heart rhythm/heart events.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests sotateltide (PMZ-1620) in people with a recent spinal cord injury. It aims to see whether the drug can improve neurological recovery after injury, especially in certain levels and types of incomplete injuries.
This study tests whether surgery to take pressure off the spinal cord, plus placing a small nerve graft, can help recovery after a severe spinal cord injury. It is for people with a recent injury who have lost all movement and feeling below the level of injury.
This trial tests whether metformin (a common diabetes drug) can reduce further damage to the spinal cord after a recent injury. If you have had a spinal cord injury in the last day, this study might help reduce long-term disability.
This trial tests whether a GLP-1 agonist (a type of diabetes medicine that also helps with weight loss) is safe and effective for people with spinal cord injury and type 2 diabetes who are not on other glucose-lowering drugs.
This trial tests whether a medicine called an SGLT2 inhibitor, which is usually used for diabetes, can help protect the brain and improve recovery when given soon after a stroke. It is for people who had a stroke within the last 3 days and have moderate to severe symptoms.
This study tests whether a medication called galantamine can help improve metabolic syndrome (a cluster of health conditions including obesity, high blood sugar, and high cholesterol) in people with chronic spinal cord injury. The goal is to see if this treatment can reduce health risks and improve overall wellness.
Hear when a new Acute Spinal Cord Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.